Trusted partner and worldwide supplier to the diagnostic testing industry for over 30 years

The interlaboratory comparisons made possible by this partnership [NIST and SeraCare] will speed NIST's efforts to overcome measurement challenges and advance cancer-detection technology broadly for the biomedical community. Studies have shown that circulating tumor DNA can be detected in many cancers and it can be used to monitor therapeutic progress. - Kenneth Cole, a group leader in NIST's Biosystems and Biomaterials Division

Seraseq reference materials offer a comprehensive and customizable set of mutations which are ideally suited to the comprehensive nature of the TOMA OS-Seq reagent kit. More importantly, we share the vision of a strong quality and regulatory approach when bringing validated NGS-based tumor profiling assays to market. - Federico Goodsaid, Ph.D., Vice President of Assay Development and Regulatory Affairs

Understanding and characterizing any NGS assay for liquid biopsy samples will require well-defined reference reagents. Standards like Seraseq ctDNA reference material allow the community to first understand ctDNA properties, optimize assays and then ultimately use ctDNA in innovative assays to detect and monitor cancer burdens within samples. In turn, this type of work will lay the foundation for transforming future cancer treatments. - Dr. Timothy Harkins, CEO of Swift Biosciences

It's really nice to work with SeraCare these years. I want to say thank you so much for all the efforts since we began working together. SeraCare has done an excellent job in supporting our business and I know that you will continue to do so in the future. I am always impressed with SeraCare's professionalism, passion, innovation, and attention to detail. Thank you again for everything!